Conclusion: This trial is the first to report that MRI tenosynovitis independently predicts both X-ray and MRI damage progression in RA patients in clinical remission. Further studies are needed to confirm MRI-determined tenosynovitis as predictor of progressive joint destruction in RA clinical remission.

REFERENCES:

- [1] Lillegraven, et al. Ann Rheum Dis 2012
- [2] Møller-Bisgaard et al. JAMA, accepted Dec 2018

Acknowledgement: AbbVie for financial study support

Disclosure of Interests: Signe Møller-Bisgaard Grant/research support from: Grants and non financial support from AbbVie during the conduct of the study, Speakers bureau: BMS, Kim Horslev-Petersen Grant/research support from: AbbVie during the conduct of the study, Bo Ejbjerg: None declared, Merete L. Hetland Grant/research support from: BMS, MSD, AbbVie, Roche, Novartis, Biogen, Pfizer, Consultant for: Eli Lilly, Speakers bureau: Orion Pharma, Biogen, Pfizer, CellTrion, Merck, Samsung Bioepis, Lykke Ørnbjerg Grant/research support from: Unrestricted grant: Novartis, Daniel Glinatsi: None declared, Jakob Møllenbach Møller: None declared, Mikael Boesen Grant/research support from: Image Analysis Group, Eli Lilly, UCB, AbbVie, Esaote, Kristian Stengaard-Pedersen: None declared, Ole Madsen Grant/research support from: Sobi, AbbVie, Merck Sharp and Dohme, Pfizer, Eli Lilly, Celgene, Novartis, UCB, Sanofi Aventis, Roche, Amgen and BMS, Bente Jensen: None declared, Jan Villadsen: None declared, Ellen Margrethe Hauge Grant/research support from: Have received grants from Roche and Novartis, outside the submitted work., Speakers bureau: Have received personal fees from MSD, Pfizer, UCB and Sobi, Philip Bennett Grant/research support from: Eli Lilly, Merck Sharp and Dohme, Novartis, Oliver Hendricks Grant/research support from: AbbVie, Novartis, Karsten Asmussen: None declared, Marcin Kowalski: None declared, Hanne Merete Lindegaard: None declared, Henning Bliddal Grant/research support from: AbbVie, Oak Foundation, Niels Steen Krogh: None declared, Torkell Ellingsen: None declared, Agnete Nielsen: None declared, Lone Balding: None declared, Anne Grethe Jurik: None declared, Henrik Thomsen: None declared, Mikkel Østergaard Grant/research support from: Abbvie, Celgene, Centocor, Merck, Novartis, Consultant for: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB
DOI: 10.1136/annrheumdis-2019-eular.2006

FRIDAY, 14 JUNE 2019

Complement and autoimmunity – emerging therapeutic opportunities

OP0332

COMPLEMENT FACTOR EXPRESSION AND ACTIVATION IN OSTEOARTHRITIS JOINT COMPARTMENTS

Elisa Assirelli, Lia Pulsatelli, Paolo Dolzani, Olga Addimanda, Gina Lisignoli, Erminia Mariani, Riccardo Meliconi. IRCCS, Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy

Background: Several studies have identified a central role for the activation of the complement system in the pathogenesis of OA, finding an abnormally high expression and activation of complement in human osteoarthritic joints and the specific contribution of complement (C) components 5 and 6 and the membrane attack complex (MAC) (1). The complement system consists of several proteins which contribute to an enzymatic cascade ending in lysis. Two main, different pathways converge into C3 factor activation. In the classical pathway C4 is involved, while in alternative pathways Factor-b (FB) is involved.

Objectives: The aim of this study was to investigate the expression of complement factors (C3, C4 and FB) and activation fragments (C3a, C5a, FBa, MAC) in OA joint tissues.

Methods: Osteochondral biopsies from 33 patients (16 OA, 12 Rheumatoid Arthritis-RA and 15 Posttraumatic cases-PT) who underwent knee, hip or shoulder arthroplasty were collected. Immunohistochemistry and quantitative Imaging analysis were performed to analyze C3, C4 and CFB expression. Cartilage pathology was evaluated utilizing Mankin score. Chondrocytes, synoviocytes, cartilage and synovial biopsies were obtained from 11 OA patients undergoing joint replacement surgery. Cultures were set up with or without pro-inflammatory (IL-1 β) stimulus. Culture supernatants were analyzed for C3a, C5a, CFBa and C5b-9 production using enzyme-linked immuno-sorbent assay (ELISA). Statistical analysis was performed utilizing Wilcoxon matched pairs test and Mann Whitney's test, using Graph Pad Prism software.

Results: In osteochondral biopsies, C factor expression was located in bone marrow and in a few subchondral bone cells. C3 was the most expressed factor in all

patient subtypes while factor C4 had a very low expression, except for some sporadic cases. (OA: C3 vs FactorB $p=0.0280$, C3 vs C4 $p=0.0005$; RA: C3 vs FactorB $p=0.0269$, C3 vs C4 $p=0.0005$; PT: C3 vs FactorB $p=ns$, C3 vs C4 $p=0.0001$) CFB was significantly augmented in PT and was not significantly different between OA and RA. C factors expression did not correlate with Mankin score or with the joint type (knee, hip or shoulder). Cell positivity was mainly present in the subchondral bone (bone marrow) whereas cartilage was almost negative. As to activation fragments, C3a was the most produced factor (vs C5a and CFBa $p<0.0005$) but no differences were found between cultured chondrocytes and synoviocytes (vs synovial tissue $p<0.0005$) and its production was not stimulated by proinflammatory stimulus. C5a production in cartilage was significantly higher than in chondrocytes and synovial tissue (both $p<0.0005$) but no differences were found between cartilage and synoviocytes. CFBa was induced by IL-1 β in synovial tissue. C5b-9 production was undetectable in chondrocytes and synoviocytes cell culture supernatants. In cartilage C5b-9 production was decreased by IL-1 β stimulus while in synovium it was increased, although not significantly.

Conclusion: Complement factors were expressed mainly in bone marrow and in a few subchondral bone cells, but not in cartilage. Complement activating fragments are produced by chondrocytes and synoviocytes. The dissimilar expression of activating fragments by different cell types could suggest various C activating mechanisms in joint tissues.

REFERENCE:

- [1] Wang Q, et al. Nat Med 2011;17:1674-1679.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.5449

SATURDAY, 15 JUNE 2019

Novel autoantibodies in RMD: a neverending quest?

OP0333

RISING ACPA IGG VARIABLE DOMAIN GLYCOSYLATION PRE-DISEASE ASSOCIATES WITH AN INCREASE IN AUTOANTIBODY LEVELS AND THE DEVELOPMENT OF RHEUMATOID ARTHRITIS

Theresa Kissel¹, Karin van Schie¹, Lise Hafkenscheid¹, Anders Lundquist², Hans Ulrich Scherer¹, Heidi Kokkonen³, Rene Toes¹, Solbritt Rantapää Dahlqvist³.

¹Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands;

²Umeå University, Statistics, Umea, Sweden; ³Umeå University, Public Health and Clinical Medicine, Umea, Sweden

Background: Anti-citrullinated protein antibodies (ACPA) are present in the majority of rheumatoid arthritis (RA) patients (60-70%) and play a pivotal role in disease development¹. ACPA IgGs are unique in a way that they are abundantly N-glycosylated within their variable regions². These variable domain (V-domain) glycans are found on over 90% of ACPAs present in sera from RA-patients³. To undergo N-linked glycosylation, a consensus sequence in the protein backbone is required (N-X-S/T, where X $\neq$ P)⁴. Recently, it was shown that the N-linked glycosylation sites in ACPA-IgG V-domains are introduced during somatic hypermutation and that the introduction of such sites likely conveys a selective advantage to ACPA expressing B-cells⁵. However, it is currently unknown, whether ACPA-expressing B-cells already introduced glycosylation-sites into their V-domains before disease onset or when ACPA-V-domain glycosylation occurs.

Objectives: Investigate the appearance of ACPA V-domain glycosylation in pre-symptomatic individuals and RA patients.

Methods: In a case-control study, individuals (n=201) from the Medical Biobank, who were sampled before onset of symptoms (mean $\pm$ SEM predating time; 5.8 $\pm$ 0.3 years) (140 aCCP+ and 61 aCCP-), and after diagnosis of RA (n=99, 94 aCCP+ and 5 aCCP-) and randomly selected control samples (n=43, 3 aCCP+ and 40 aCCP-) were analyzed for their ACPA IgG V-domain glycosylation levels. ACPA IgGs were affinity purified, N-linked glycans released, and 2-AA labeled for further analysis using UHPLC⁶. Data calibration and integration was performed and a cut-off defined. Samples below the cut-off were determined as non-detectable and excluded from the analysis. The percentage V-domain glycosylation was calculated as described previously³. Statistical calculations were performed using SPSS.

Results: Our data indicated that ACPA IgG V-domain glycans are already present years before symptom onset, in pre-symptomatic individuals who subsequently will develop RA. Analysis of matched pairs showed a significant increase of ACPA V-domain glycosylation in RA patients compared to individuals pre-disease ($p<0.001$). The results showed that ACPA N-glycosylation was correlated with anti-CCP concentrations pre-disease ($r_s=0.504$, $p<0.001$), while no such association can be found after RA onset. Further, V-domain glycosylation levels increase closer to symptom onset.